参考文献/References:
[1] Damman P,van ’t Hof AW,Ten Berg JM,et al. 2015 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation:comments from the Dutch ACS working group[J]. Neth Heart J,2017,25(3):181-185.
[2] Neumann FJ,Sousa-Uva M,Ahlsson A,et al.2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Eur Heart J,2019,40(2):87-165.
[3] Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS[J]. Kardiol Pol,2017,75(12):1217-1299.
[4] Ibanez B,James S,Agewall S,et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation:The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC)[J]. Eur Heart J,2018,39(2):119-177.
[5] Fan W,Plent S,Prats J,et al. Trends in P2Y12 inhibitor use in patients referred for invasive evaluation of coronary artery disease in contemporary US practice[J]. Am J Cardiol,2016,117(9):1439-1443.
[6] Tantry US,Bliden KP,Wei C,et al. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel:the ONSET/OFFSET and RESPOND genotype studies[J]. Circ Cardiovasc Genet,2010,3(6):556-566.
[7] Mega JL,Topol EJ,Sabatine MS. CYP2C19 genotype and cardiovascular events[J]. JAMA,2012,307(14):1482-1483,1484-1485.
[8] Zhong Z,Hou J,Zhang Q,et al. Effect of cytochrome P450 2C19 polymorphism on adverse cardiovascular events after drug-eluting stent implantation in a large Hakka population with acute coronary syndrome receiving clopidogrel in southern China[J]. Eur J Clin Pharmacol,2018,74(4):423-431.
[9] Empey PE,Stevenson JM,Tuteja S,et al. Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy[J]. Clin Pharmacol Ther,2018,104(4):664-674.
[10] Price MJ,Murray S,Angiolillo DJ,et al. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous coronary intervention:the GIFT (Genotype Information and Functional Testing) study[J]. J Am Coll Cardiol,2012,59(22):1928-1937.
[11] Mega JL,Hochholzer W,Frelinger AR,et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease[J]. JAMA,2011,306(20):2221-2228.
[12] Roberts JD,Wells GA,le May MR, et al. Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial[J]. Lancet,2012,379(9827):1705-1711.
[13] Sardella G,Calcagno S,Mancone M,et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel:the RESET GENE trial[J]. Circ Cardiovasc Interv,2012,5(5):698-704.
[14] Scott SA,Sangkuhl K,Stein CM,et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy:2013 update[J]. Clin Pharmacol Ther,2013,94(3):317-323.
[15] O’Gara PT,Kushner FG,Ascheim D,et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction:a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2013,127(4):e362-e425.
[16] Amsterdam EA,Wenger NK,Brindis RG,et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes:executive summary:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines[J]. Circulation,2014,130(25):2354-2394.
[17] Levine GN,Bates ER,Bittl JA,et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease:A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines[J]. J Am Coll Cardiol,2016,68(10):1082-1115.
[18] Valgimigli M,Bueno H,Byrne RA,et al. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS:The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J,2018,39(3):213-260.
[19] Cavallari LH,Lee CR,Beitelshees AL,et al. Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention[J]. JACC Cardiovasc Interv,2018,11(2):181-191.
[20] Notarangelo FM,Maglietta G,Bevilacqua P,et al. Pharmacogenomic Approach to Selecting Antiplatelet Therapy in Patients With Acute Coronary Syndromes:The PHARMCLO Trial[J]. J Am Coll Cardiol,2018,71(17):1869-1877.
[21] Tuteja?DS.?Assessment of prospective CYP2C19 genotype guided dosing of antiplatelet therapy in percutaneous coronary intervention (ADAPT)[R]. American College of Cardiology Annual Scientific Session (ACC 2018), Orlando, FL.
[22] Lee CR,Sriramoju VB,Cervantes A,et al. Clinical outcomes and sustainability of using CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention[J]. Circ Genom Precis Med,2018,11(4):e2069.
[23] Cavallari LH,Franchi F,Rollini F,et al. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention[J]. J Transl Med,2018,16(1):92.
相似文献/References:
[1]朱佩,袁晋青.P2Y12受体拮抗剂与质子泵抑制剂相互作用的研究进展[J].心血管病学进展,2015,(5):570.[doi:10.3969/j.issn.1004-3934.2015.05.012]
ZHU Pei,YUAN Jinqing.Review of Interactions Between P2Y12 Receptor Antagonists and
Proton Pump Inhibitors[J].Advances in Cardiovascular Diseases,2015,(6):570.[doi:10.3969/j.issn.1004-3934.2015.05.012]
[2]陈凯磊 胡闻竹 苏冠华.P2Y12抑制剂与癌症风险的相关性研究进展[J].心血管病学进展,2020,(8):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
CHEN Kailei,HU Wenzhu,SU Guanhua.Advances in Studies on the Correlation between P2Y12 Inhibitors and Cancer Risk[J].Advances in Cardiovascular Diseases,2020,(6):798.[doi:10.16806/j.cnki.issn.1004-3934.2020.08.004]
[3]周锐 赵飞飞 钱阳 余文静 王大新..氯吡格雷与替格瑞洛的安全性和有效性在东亚急性心肌梗死患者的比较：系统回顾和荟萃分析[J].心血管病学进展,2021,(6):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
ZHOU RuiZHAO Feifei QIAN YangYU WenjingWANG Daxin.Comparison of the Safety and Efficacy of Clopidogrel Versus Ticagrelor in Patients with Acute Myocardial Infarction in East Asia:a Systematic Review and Meta-Analysis[J].Advances in Cardiovascular Diseases,2021,(6):560.[doi:10.16806/j.cnki.issn.1004-3934.2021.06.020]
[4]王亚辉 杨滨.血液透析对行经皮冠状动脉介入治疗的患者合用阿司匹林及氯吡格雷抗血小板聚集的影响[J].心血管病学进展,2021,(10):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]
WANG YahuiYANG Bin.Effect of Hemodialysis on the Antiplatelet Aggregation of Patients Undergoing Percutaneous Coronary Intervention Combined with Aspirin and Clopidogrel[J].Advances in Cardiovascular Diseases,2021,(6):946.[doi:10.16806/j.cnki.issn.1004-3934.2021.10.020]